Polar Capital Holdings’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Polar Capital Holdings’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-250,000	Closed	-$5.85M	–	383
2021 Q1	$5.85M	Sell	250,000 -750,000	-75%	-$22.7M	0.04%	241
2020 Q4	$28.8M	Buy	+1,000,000	New	+$25.2M	0.17%	125

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital Holdings's CNST Position: Q2 2021 in Review

Polar Capital Holdings sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 250,000 shares — an estimated $5.85M sold.

Polar Capital Holdings first reported a position in CNST in Q4 2020 and held it in 2 quarters. The position peaked at $28.8M in Q4 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

Polar Capital Holdings reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Polar Capital Holdings sold 250,000 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $5.85M.
Polar Capital Holdings first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
Polar Capital Holdings's Constellation Pharmaceuticals, Inc. position peaked at $28.8M in Q4 2020.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Polar Capital Holdings's 13F filing for Q2 2021, filed 16 Aug 2021.